Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer


Tonyali O., Coskun U., SENER N., İNANÇ M., Akman T., OKSUZOGLU B., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.12, pp.2145-2151, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 138 Issue: 12
  • Publication Date: 2012
  • Doi Number: 10.1007/s00432-012-1296-x
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.2145-2151

Abstract

Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.